MedPath

NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study

Not Applicable
Terminated
Conditions
Breast Reconstruction
Breast Implant Revision
Breast Augmentation
Interventions
Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Registration Number
NCT01870869
Lead Sponsor
Allergan
Brief Summary

This study is a prospective, multicenter, nonrandomized study to provide access to and evaluate the safety and effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X-Style and L-Style Breast Implants for breast augmentation, reconstruction, or revision.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
1951
Inclusion Criteria

For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study under the inclusion criteria below and received NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts; or be planning to be implanted with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and meet the inclusion criteria listed below:

  • Female, age 18 or older (age 22 or older for breast augmentation participants who are implanted under Protocol 410CAXL-001)

  • Present with 1 or more of the following conditions:

    • Primary breast augmentation (i.e., no previous breast implant surgery) indicated for participant dissatisfaction with size or shape of breast (e.g., mammary hypoplasia), asymmetry, ptosis, or aplasia
    • Primary breast reconstruction (i.e., no previous breast implant surgery other than implantation of tissue expanders or contralateral augmentation for asymmetry) indicated, in the affected breast, for mastectomy for cancer, prophylactic mastectomy, or breast trauma, (resulting in mastectomy) and for the unaffected breast, contralateral asymmetry (may be performed on the date of the mastectomy or the date when permanent implants are placed in the reconstructed breast)
    • Breast implant revision surgery (i.e., removal and replacement of breast implants) indicated for previous augmentation or reconstruction with silicone-filled or saline-filled breast implants
  • Has adequate tissue available to cover implants

Read More
Exclusion Criteria

For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study and did not meet the exclusion criteria listed below or plan to undergo implantation with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and does not meet the exclusion criteria listed below:

  • Has an advanced fibrocystic disease considered to be premalignant without accompanying subcutaneous mastectomy
  • Has an existing carcinoma of the breast, without mastectomy
  • Has an abscess or infection in the body at the time of enrollment
  • Is pregnant or nursing
  • Has any disease, including uncontrolled diabetes (e.g., hemoglobin A1c (HbA1c) > 8%), that is clinically known to impact wound healing ability
  • Shows tissue characteristics that are clinically incompatible with mammaplasty, such as tissue damage resulting from radiation, inadequate tissue, compromised vascularity, or ulceration
  • Has or is under treatment for any condition that may constitute an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)
  • Shows psychological characteristics that may be incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body dysmorphic disorder)
  • Is not willing to undergo further surgery for revision, if medically required
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ReconstructionAnatomically shaped, silicone-filled breast implants with low height/projection or extra-full projectionWomen who had breast reconstruction with NATRELLE® 410 implants.
AugmentationAnatomically shaped, silicone-filled breast implants with low height/projection or extra-full projectionWomen who had breast augmentation with NATRELLE® 410 implants.
Revision-AugmentationAnatomically shaped, silicone-filled breast implants with low height/projection or extra-full projectionWomen who had revision of previous breast augmentation with NATRELLE® 410 implants.
Revision-ReconstructionAnatomically shaped, silicone-filled breast implants with low height/projection or extra-full projectionWomen who had revision of previous breast reconstruction with NATRELLE® 410 implants.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants According to Investigator Satisfaction With Implants5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)

The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: "Definitely satisfied" or "Somewhat satisfied" is reported.

Percentage of Participants According to Participant Satisfaction With Implants5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)

The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: "Definitely satisfied" or "Somewhat satisfied" is reported.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With Local Complications5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)

Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .

Percentage of Participants With Reoperations5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)

Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.

Percentage of Participants With Implant Removal With or Without Replacement5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)

Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.

Trial Locations

Locations (57)

John Decorato

🇺🇸

Staten Island, New York, United States

Raymond Isakov

🇺🇸

Cleveland, Ohio, United States

Roy Hong

🇺🇸

Palo Alto, California, United States

Gary Snider

🇺🇸

Denver, Colorado, United States

Orlando De Lucia

🇺🇸

Farmington, Connecticut, United States

Lewis Berger

🇺🇸

Tampa, Florida, United States

Paul Davis

🇺🇸

Shreveport, Louisiana, United States

Schuyler Meltis

🇺🇸

Hannibal, Missouri, United States

Peter Hyans

🇺🇸

Berkeley Heights, New Jersey, United States

Isaac Starker

🇺🇸

Florham Park, New Jersey, United States

Caroline Glicksman

🇺🇸

Sea Girt, New Jersey, United States

Robert Hein

🇺🇸

Oklahoma City, Oklahoma, United States

Kristina D. O'Shaughnessy

🇺🇸

Nashville, Tennessee, United States

John Sherman

🇺🇸

New York, New York, United States

John Renucci

🇺🇸

Grand Rapids, Michigan, United States

Tad Heinz

🇺🇸

Colorado Springs, Colorado, United States

Janet Turkle

🇺🇸

Carmel, Indiana, United States

Patricia McGuire

🇺🇸

Creve Coeur, Missouri, United States

Charles Nathan

🇺🇸

Chesterfield, Missouri, United States

Julene Samuels

🇺🇸

Louisville, Kentucky, United States

Perry Johnson

🇺🇸

Omaha, Nebraska, United States

Anthony Griffin

🇺🇸

Beverly Hills, California, United States

Eric Bachelor

🇺🇸

Pleasanton, California, United States

Peter Johnson

🇺🇸

Des Plaines, Illinois, United States

Stephen Madry

🇺🇸

Elk Grove Village, Illinois, United States

Brad Storm

🇺🇸

Olathe, Kansas, United States

Steven Teitelbaum

🇺🇸

Santa Monica, California, United States

Bradley Bengtson

🇺🇸

Grand Rapids, Michigan, United States

Terrence Murphy

🇺🇸

Englewood, Colorado, United States

Herluf Lund Jr.

🇺🇸

Chesterfield, Missouri, United States

Gerard Mosiello

🇺🇸

Tampa, Florida, United States

Patrick Maxwell

🇺🇸

Nashville, Tennessee, United States

William Adams

🇺🇸

University Park, Texas, United States

Mary Powers

🇺🇸

Long Beach, California, United States

Laurence Berkowitz

🇺🇸

Campbell, California, United States

Timothy Mickel

🇺🇸

Monroe, Louisiana, United States

Marc Alan Drimmer

🇺🇸

Princeton, New Jersey, United States

Mark Jewell

🇺🇸

Eugene, Oregon, United States

Peter Hetzler

🇺🇸

Little Silver, New Jersey, United States

Gavin Dry

🇺🇸

Bellevue, Washington, United States

Bruce Van Natta

🇺🇸

Indianapolis, Indiana, United States

Christine Kelley-Patteson

🇺🇸

Indianapolis, Indiana, United States

Jeffrey Friedman

🇺🇸

Houston, Texas, United States

Douglas Reavie

🇺🇸

San Diego, California, United States

James Namnoum

🇺🇸

Atlanta, Georgia, United States

Tracy Pfeifer

🇺🇸

New York, New York, United States

Robert Jacobs

🇺🇸

Port Jefferson Station, New York, United States

Derek Shadid

🇺🇸

Oklahoma City, Oklahoma, United States

Craig Colville

🇺🇸

Toledo, Ohio, United States

William Carpenter

🇺🇸

Dallas, Texas, United States

Frank Barone

🇺🇸

Toledo, Ohio, United States

John Lettieri

🇺🇸

Spartanburg, South Carolina, United States

Natan Yaker

🇺🇸

Plano, Texas, United States

Lloyd Gayle

🇺🇸

New York, New York, United States

Steven Morris

🇺🇸

Midland, Michigan, United States

Gloria Duda

🇺🇸

McLean, Virginia, United States

Allen Gabriel

🇺🇸

Vancouver, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath